Barclays Rates Nuvalent (NUVL) hold, $124 Price Target
Barclays analyst Etzer Darout adjusted the rating on Nuvalent, Inc. to hold on June 10, 2026, a 0.61% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Barclays rated Nuvalent, Inc. ($NUVL) "hold" with a $124 price target on June 10, 2026.
Since the rating, $NUVL is up 0.0% after 1 week and up 0.1% to date (from the $123.35 close on Jun 10, 2026).
NUVL
Nuvalent, Inc.
Key Points
- Barclays analyst Etzer Darout lowered the rating on Nuvalent, Inc. (NUVL) to hold with a $124.00 price target on June 10, 2026.
- Barclays's $124 price target implies 0.61% upside from Nuvalent, Inc.'s ($NUVL) current $123.25 share price.
- Nuvalent shares recently traded near $123.25, sitting close to their 52-week high of $123.99.
- Bernstein also weighed in with a downgrade to Market Perform and a $124.00 price target on June 24, 2026.
Get $NUVL trade alerts by text
We text you when insiders, Congress or big funds trade $NUVL. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Nuvalent, Inc. alert may contain errors. Disclosures
Barclays Adjusts Nuvalent Stance
Barclays adjusted its outlook on Nuvalent, Inc. (NGM: NUVL) on June 10, 2026. Analyst Etzer Darout lowered the rating on the clinical-stage biotech firm to hold while setting a price target of $124.00. The updated stance comes as Wall Street monitors the company's ongoing development of targeted cancer therapies.
Nuvalent Stock Nears 52-Week Highs
Nuvalent shares recently changed hands at $123.25, trading just below the top end of its 52-week range of $71.13 to $123.99. The stock has experienced strong upward momentum, sitting well above its 50-day moving average of $114.66 and its 200-day moving average of $105.26. With a market capitalization of roughly $9.81 billion and a beta of 1.14, the equity shows slightly higher volatility than the broader market.
$NUVL price target
Nuvalent, Inc. daily closes and this analyst's $124 target. Not advice.
Bernstein Joins With Market Perform Rating
Other Wall Street firms have also revisited their expectations for the biotechnology company. On June 24, 2026, Bernstein downgraded the stock to Market Perform and lowered its price target to $124.00 from a prior target of $172.00. Across the broader analyst community, Nuvalent carries a consensus recommendation key of hold, backed by a mean price target of $124.00 based on nine analyst opinions.
Inside Nuvalent's Pipeline Focus
Nuvalent, Inc. is a Cambridge, Massachusetts-based biopharmaceutical company founded in 2017 that focuses on developing precision treatments for cancer patients. Its pipeline includes lead product candidates like Zidesamtinib for ROS1-positive non-small cell lung cancer, Neladalkib for ALK-positive tumors, and NVL-330 for HER2-driven cancers. These programs are designed to overcome treatment resistance and address brain metastases while avoiding off-target side effects.
What to Watch Next for NUVL
Investors will continue tracking clinical trial progress and future pipeline updates from the company's research portfolio. Because biotech valuations often hinge on clinical milestones and regulatory steps, upcoming data readouts will likely dictate how close the stock trades to current analyst price targets.
Related Filing Alerts
Source: Barclays's rating change on $NUVL (Jun 10, 2026). Written by software, not financial advice. How we make alerts